Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade) [Seeking Alpha]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Seeking Alpha
Its stock price is no longer depressed, and its guidance for 2024 is unremarkable, leading to a downgrading to a "Hold". Acquisition of commercial rights to FYCOMPA has provided it with a second revenue stream, but the deal's financial viability remains uncertain. This is my sixth Catalyst ( NASDAQ: CPRX ) article. I rated it as a tepid "Buy" in my most recent 07/2023's "Catalyst Pharmaceuticals: A New Catalyst Tilts The Scales - Just Barely" (" Just Barely "). Since Just Barely, Catalyst has performed well, up ~20%. The thesis of Just Barely pegged Catalysts as a "Buy" based on newly acquired catalysts and upon its then depressed price. As I write in early 04/2024 its price is no longer depressed. Its guidance for 2024 is unremarkable if not outright discouraging. Accordingly, for these and other reasons I discuss below, I am moving back to a "Hold". In this article I rely upon the following sources released in conjunction with its Q4, 2023 earnings on 02/29/2024 — earnings
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024GlobeNewswire
- Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company [Yahoo! Finance]Yahoo! Finance
- Parent Project Muscular Dystrophy Celebrates 30th Anniversary with Launch of PPMD Together Meeting Series in Cincinnati, Ohio [Yahoo! Finance]Yahoo! Finance
CPRX
Earnings
- 2/28/24 - Miss
CPRX
Sec Filings
- 4/10/24 - Form 4
- 4/10/24 - Form ARS
- 4/10/24 - Form DEF
- CPRX's page on the SEC website